60 Degrees Pharmaceuticals, Inc. (SXTP)
- Previous Close
3.1600 - Open
3.5000 - Bid 2.7000 x 200
- Ask 4.1600 x 200
- Day's Range
3.2000 - 4.4200 - 52 Week Range
1.4100 - 36.0000 - Volume
1,430,380 - Avg. Volume
1,918,673 - Market Cap (intraday)
5.45M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-18.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.80
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
www.60degreespharma.comRecent News: SXTP
View More
Performance Overview: SXTP
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SXTP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SXTP
View MoreValuation Measures
Market Cap
4.65M
Enterprise Value
12.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.36
Price/Book (mrq)
--
Enterprise Value/Revenue
20.93
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-89.67%
Return on Equity (ttm)
-181.78%
Revenue (ttm)
681.35k
Net Income Avi to Common (ttm)
-8.43M
Diluted EPS (ttm)
-18.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.39M
Total Debt/Equity (mrq)
3.94%
Levered Free Cash Flow (ttm)
-648.4k
Research Analysis: SXTP
View MoreResearch Reports: SXTP
View MoreDaily – Vickers Top Insider Picks for 02/21/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/20/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/19/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/18/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.